Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 Revision

Allergic rhinitis represents a global health problem affecting 10% to 20% of the population. The Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines have been widely used to treat the approximately 500 million affected patients globally. To develop explicit, unambiguous, and transparent cli...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Journal of allergy and clinical immunology Ročník 126; číslo 3; s. 466 - 476
Hlavní autori: Brożek, Jan L., Bousquet, Jean, Baena-Cagnani, Carlos E., Bonini, Sergio, Canonica, G. Walter, Casale, Thomas B., van Wijk, Roy Gerth, Ohta, Ken, Zuberbier, Torsten, Schünemann, Holger J.
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: New York, NY Elsevier Inc 01.09.2010
Elsevier
Elsevier Limited
Predmet:
AR
ISSN:0091-6749, 1097-6825, 1097-6825
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Abstract Allergic rhinitis represents a global health problem affecting 10% to 20% of the population. The Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines have been widely used to treat the approximately 500 million affected patients globally. To develop explicit, unambiguous, and transparent clinical recommendations systematically for treatment of allergic rhinitis on the basis of current best evidence. The authors updated ARIA clinical recommendations in collaboration with Global Allergy and Asthma European Network following the approach suggested by the Grading of Recommendations Assessment, Development and Evaluation working group. This article presents recommendations about the prevention of allergic diseases, the use of oral and topical medications, allergen specific immunotherapy, and complementary treatments in patients with allergic rhinitis as well as patients with both allergic rhinitis and asthma. The guideline panel developed evidence profiles for each recommendation and considered health benefits and harms, burden, patient preferences, and resource use, when appropriate, to formulate recommendations for patients, clinicians, and other health care professionals. These are the most recent and currently the most systematically and transparently developed recommendations about the treatment of allergic rhinitis in adults and children. Patients, clinicians, and policy makers are encouraged to use these recommendations in their daily practice and to support their decisions.
AbstractList Allergic rhinitis represents a global health problem affecting 10% to 20% of the population. The Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines have been widely used to treat the approximately 500 million affected patients globally. To develop explicit, unambiguous, and transparent clinical recommendations systematically for treatment of allergic rhinitis on the basis of current best evidence. The authors updated ARIA clinical recommendations in collaboration with Global Allergy and Asthma European Network following the approach suggested by the Grading of Recommendations Assessment, Development and Evaluation working group. This article presents recommendations about the prevention of allergic diseases, the use of oral and topical medications, allergen specific immunotherapy, and complementary treatments in patients with allergic rhinitis as well as patients with both allergic rhinitis and asthma. The guideline panel developed evidence profiles for each recommendation and considered health benefits and harms, burden, patient preferences, and resource use, when appropriate, to formulate recommendations for patients, clinicians, and other health care professionals. These are the most recent and currently the most systematically and transparently developed recommendations about the treatment of allergic rhinitis in adults and children. Patients, clinicians, and policy makers are encouraged to use these recommendations in their daily practice and to support their decisions.
Background Allergic rhinitis represents a global health problem affecting 10% to 20% of the population. The Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines have been widely used to treat the approximately 500 million affected patients globally. Objective To develop explicit, unambiguous, and transparent clinical recommendations systematically for treatment of allergic rhinitis on the basis of current best evidence. Methods The authors updated ARIA clinical recommendations in collaboration with Global Allergy and Asthma European Network following the approach suggested by the Grading of Recommendations Assessment, Development and Evaluation working group. Results This article presents recommendations about the prevention of allergic diseases, the use of oral and topical medications, allergen specific immunotherapy, and complementary treatments in patients with allergic rhinitis as well as patients with both allergic rhinitis and asthma. The guideline panel developed evidence profiles for each recommendation and considered health benefits and harms, burden, patient preferences, and resource use, when appropriate, to formulate recommendations for patients, clinicians, and other health care professionals. Conclusion These are the most recent and currently the most systematically and transparently developed recommendations about the treatment of allergic rhinitis in adults and children. Patients, clinicians, and policy makers are encouraged to use these recommendations in their daily practice and to support their decisions.
Background: Allergic rhinitis represents a global health problem affecting 10% to 20% of the population. The Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines have been widely used to treat the approximately 500 million affected patients globally. Objective: To develop explicit, unambiguous, and transparent clinical recommendations systematically for treatment of allergic rhinitis on the basis of current best evidence. Methods: The authors updated ARIA clinical recommendations in collaboration with Global Allergy and Asthma European Network following the approach suggested by the Grading of Recommendations Assessment, Development and Evaluation working group. Results: This article presents recommendations about the prevention of allergic diseases, the use of oral and topical medications, allergen specific immunotherapy, and complementary treatments in patients with allergic rhinitis as well as patients with both allergic rhinitis and asthma. The guideline panel developed evidence profiles for each recommendation and considered health benefits and harms, burden, patient preferences, and resource use, when appropriate, to formulate recommendations for patients, clinicians, and other health care professionals. Conclusion: These are the most recent and currently the most systematically and transparently developed recommendations about the treatment of allergic rhinitis in adults and children. Patients, clinicians, and policy makers are encouraged to use these recommendations in their daily practice and to support their decisions.
Allergic rhinitis represents a global health problem affecting 10% to 20% of the population. The Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines have been widely used to treat the approximately 500 million affected patients globally. To develop explicit, unambiguous, and transparent clinical recommendations systematically for treatment of allergic rhinitis on the basis of current best evidence. The authors updated ARIA clinical recommendations in collaboration with Global Allergy and Asthma European Network following the approach suggested by the Grading of Recommendations Assessment, Development and Evaluation working group. This article presents recommendations about the prevention of allergic diseases, the use of oral and topical medications, allergen specific immunotherapy, and complementary treatments in patients with allergic rhinitis as well as patients with both allergic rhinitis and asthma. The guideline panel developed evidence profiles for each recommendation and considered health benefits and harms, burden, patient preferences, and resource use, when appropriate, to formulate recommendations for patients, clinicians, and other health care professionals. These are the most recent and currently the most systematically and transparently developed recommendations about the treatment of allergic rhinitis in adults and children. Patients, clinicians, and policy makers are encouraged to use these recommendations in their daily practice and to support their decisions.
Allergic rhinitis represents a global health problem affecting 10% to 20% of the population. The Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines have been widely used to treat the approximately 500 million affected patients globally.BACKGROUNDAllergic rhinitis represents a global health problem affecting 10% to 20% of the population. The Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines have been widely used to treat the approximately 500 million affected patients globally.To develop explicit, unambiguous, and transparent clinical recommendations systematically for treatment of allergic rhinitis on the basis of current best evidence.OBJECTIVETo develop explicit, unambiguous, and transparent clinical recommendations systematically for treatment of allergic rhinitis on the basis of current best evidence.The authors updated ARIA clinical recommendations in collaboration with Global Allergy and Asthma European Network following the approach suggested by the Grading of Recommendations Assessment, Development and Evaluation working group.METHODSThe authors updated ARIA clinical recommendations in collaboration with Global Allergy and Asthma European Network following the approach suggested by the Grading of Recommendations Assessment, Development and Evaluation working group.This article presents recommendations about the prevention of allergic diseases, the use of oral and topical medications, allergen specific immunotherapy, and complementary treatments in patients with allergic rhinitis as well as patients with both allergic rhinitis and asthma. The guideline panel developed evidence profiles for each recommendation and considered health benefits and harms, burden, patient preferences, and resource use, when appropriate, to formulate recommendations for patients, clinicians, and other health care professionals.RESULTSThis article presents recommendations about the prevention of allergic diseases, the use of oral and topical medications, allergen specific immunotherapy, and complementary treatments in patients with allergic rhinitis as well as patients with both allergic rhinitis and asthma. The guideline panel developed evidence profiles for each recommendation and considered health benefits and harms, burden, patient preferences, and resource use, when appropriate, to formulate recommendations for patients, clinicians, and other health care professionals.These are the most recent and currently the most systematically and transparently developed recommendations about the treatment of allergic rhinitis in adults and children. Patients, clinicians, and policy makers are encouraged to use these recommendations in their daily practice and to support their decisions.CONCLUSIONThese are the most recent and currently the most systematically and transparently developed recommendations about the treatment of allergic rhinitis in adults and children. Patients, clinicians, and policy makers are encouraged to use these recommendations in their daily practice and to support their decisions.
Author Baena-Cagnani, Carlos E.
van Wijk, Roy Gerth
Casale, Thomas B.
Zuberbier, Torsten
Brożek, Jan L.
Canonica, G. Walter
Schünemann, Holger J.
Bonini, Sergio
Ohta, Ken
Bousquet, Jean
Author_xml – sequence: 1
  givenname: Jan L.
  surname: Brożek
  fullname: Brożek, Jan L.
  organization: Department of Clinical Epidemiology and Biostatistics and Medicine, McMaster University, Hamilton, Ontario, Canada
– sequence: 2
  givenname: Jean
  surname: Bousquet
  fullname: Bousquet, Jean
  organization: Service des Maladies Respiratoires, Hôpital Arnaud de Villeneuve, Montpellier, France
– sequence: 3
  givenname: Carlos E.
  surname: Baena-Cagnani
  fullname: Baena-Cagnani, Carlos E.
  organization: Faculty of Medicine, Catholic University of Córdoba, Córdoba, Argentina
– sequence: 4
  givenname: Sergio
  surname: Bonini
  fullname: Bonini, Sergio
  organization: Institute of Neurobiology and Molecular Medicine—CNR, Rome, Italy
– sequence: 5
  givenname: G. Walter
  surname: Canonica
  fullname: Canonica, G. Walter
  organization: Allergy and Respiratory Diseases, DIMI, Department of Internal Medicine, University of Genoa, Genoa, Italy
– sequence: 6
  givenname: Thomas B.
  surname: Casale
  fullname: Casale, Thomas B.
  organization: Division of Allergy and Immunology, Department of Medicine, Creighton University, Omaha, Neb
– sequence: 7
  givenname: Roy Gerth
  surname: van Wijk
  fullname: van Wijk, Roy Gerth
  organization: Section of Allergology, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
– sequence: 8
  givenname: Ken
  surname: Ohta
  fullname: Ohta, Ken
  organization: Division of Respiratory Medicine and Allergology, Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan
– sequence: 9
  givenname: Torsten
  surname: Zuberbier
  fullname: Zuberbier, Torsten
  organization: Department of Dermatology and Allergy, Charité Universitätsmedizin, Berlin, Germany
– sequence: 10
  givenname: Holger J.
  surname: Schünemann
  fullname: Schünemann, Holger J.
  email: schuneh@mcmaster.ca
  organization: Department of Clinical Epidemiology and Biostatistics and Medicine, McMaster University, Hamilton, Ontario, Canada
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23238968$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/20816182$$D View this record in MEDLINE/PubMed
BookMark eNqFkltr3DAQhUVJaTZp_0AfiqGUtA_ejmzr4lAKJvSyNFDYts9ClseJXK-8lexA_n1kdkNgocmTkPjOEXPOnJAjNzgk5DWFJQXKP3bLThu7zCA-AF9CIZ6RBYVSpFxm7IgsAEqaclGUx-QkhA7iPZflC3KcgaScymxBflR9j_7KmmR9bZ0dbUi0axI7hmS12WozJoNLqjBeb3Tyvlqvqg_J1WQb7K3DcJ7MfydrvLHBDu4led7qPuCr_XlK_nz98vvie3r589vqorpMDadiTLmWRVPzkguEumgK2bSQi4LVBSuhbUFzY1BzxjLUKKTJa1oKjrnRILUs8_yUnO18t374N2EY1cYGg32vHQ5TUJIKDgVnT5OCFTFIkBDJtwdkN0zexTEUZcByAEazSL3ZU1O9wUZtvd1of6vu84zAuz2gg9F967UzNjxweRYL4DJycscZP4TgsVXGjnqMIY5e215RUHPFqlNzxWqOWQFXseIozQ6k9-6Pij7tRBh7ubHoVTAWncHGejSjagb7uPzzgdzEBbBxwr94i-EhKhUyBerXvHjz3lGIJkzMuZz_3-Cp3-8ATvDixA
CODEN JACIBY
CitedBy_id crossref_primary_10_1097_ACI_0000000000000150
crossref_primary_10_1136_archdischild_2013_304446
crossref_primary_10_1136_dtb_2018_000014
crossref_primary_10_1007_s11812_011_0010_2
crossref_primary_10_12968_hmed_2023_0212
crossref_primary_10_1016_j_jaci_2016_01_021
crossref_primary_10_1007_s40521_013_0005_6
crossref_primary_10_1111_all_13438
crossref_primary_10_1007_s15007_022_5060_5
crossref_primary_10_1016_j_jaci_2024_10_007
crossref_primary_10_3389_fphar_2022_935943
crossref_primary_10_1016_j_anai_2017_08_012
crossref_primary_10_1016_j_jaip_2023_05_022
crossref_primary_10_1016_j_amjcard_2012_08_027
crossref_primary_10_1016_j_ijporl_2017_04_006
crossref_primary_10_1016_j_jpeds_2018_06_053
crossref_primary_10_1111_j_1398_9995_2011_02682_x
crossref_primary_10_1186_s13223_020_00468_4
crossref_primary_10_2196_45364
crossref_primary_10_1007_s11882_012_0331_y
crossref_primary_10_1177_1945892420920499
crossref_primary_10_1016_j_jep_2018_11_037
crossref_primary_10_1111_all_12364
crossref_primary_10_1016_j_bjorl_2016_08_009
crossref_primary_10_1016_j_jaip_2021_02_035
crossref_primary_10_1155_2015_187620
crossref_primary_10_1111_all_12124
crossref_primary_10_1186_s13063_022_06020_6
crossref_primary_10_1016_j_imbio_2014_11_004
crossref_primary_10_1111_all_14786
crossref_primary_10_1007_s00405_019_05304_z
crossref_primary_10_1073_pnas_1300512110
crossref_primary_10_1016_j_cegh_2019_12_018
crossref_primary_10_1016_j_bjorl_2024_101398
crossref_primary_10_1016_j_pharmthera_2022_108115
crossref_primary_10_1111_pai_13038
crossref_primary_10_1016_j_arbr_2013_03_004
crossref_primary_10_2500_ar_2014_5_0089
crossref_primary_10_1111_all_12370
crossref_primary_10_1159_000355953
crossref_primary_10_4168_aair_2020_12_2_238
crossref_primary_10_3109_07853890_2011_595426
crossref_primary_10_3109_02770903_2013_819105
crossref_primary_10_1016_j_jaip_2023_05_011
crossref_primary_10_2217_cpr_12_4
crossref_primary_10_1111_pai_12136
crossref_primary_10_1155_2016_5782317
crossref_primary_10_1016_j_jaci_2011_01_069
crossref_primary_10_1007_s12325_015_0192_6
crossref_primary_10_1111_all_12383
crossref_primary_10_1016_j_bjorl_2017_10_006
crossref_primary_10_1038_s41533_020_00195_8
crossref_primary_10_1007_s11726_016_0962_y
crossref_primary_10_1186_s12950_024_00415_9
crossref_primary_10_1007_s40521_013_0007_4
crossref_primary_10_1186_s13052_018_0519_4
crossref_primary_10_1155_2020_7196981
crossref_primary_10_1017_S0022215114000450
crossref_primary_10_1017_S0022215114000693
crossref_primary_10_1111_pai_12126
crossref_primary_10_1016_j_intimp_2024_113644
crossref_primary_10_1016_j_anai_2015_05_017
crossref_primary_10_1016_j_anai_2020_08_005
crossref_primary_10_1016_j_jaci_2011_01_070
crossref_primary_10_1177_2152656718789519
crossref_primary_10_1185_03007995_2011_648263
crossref_primary_10_1016_j_jaci_2011_01_071
crossref_primary_10_1038_ejcn_2014_13
crossref_primary_10_11603_24116_4944_2025_1_15409
crossref_primary_10_2217_cpr_14_41
crossref_primary_10_1016_j_explore_2022_02_006
crossref_primary_10_1002_jcph_478
crossref_primary_10_1136_dtb_2014_2_0237
crossref_primary_10_1155_2018_9138904
crossref_primary_10_3109_13880209_2014_982299
crossref_primary_10_1373_jalm_2018_026526
crossref_primary_10_1016_j_jaci_2013_03_013
crossref_primary_10_1185_03007995_2012_672405
crossref_primary_10_1016_j_anai_2018_01_015
crossref_primary_10_1097_MOO_0b013e328347afd0
crossref_primary_10_1155_2020_5979708
crossref_primary_10_4168_aair_2018_10_4_370
crossref_primary_10_1007_s00011_012_0464_4
crossref_primary_10_35420_jcohns_2018_29_1_42
crossref_primary_10_1111_all_12164
crossref_primary_10_1186_s13223_023_00793_4
crossref_primary_10_1007_s11010_014_2142_z
crossref_primary_10_1111_cea_14604
crossref_primary_10_1517_14728214_2016_1139082
crossref_primary_10_1159_000494507
crossref_primary_10_1016_j_phymed_2023_154948
crossref_primary_10_1016_j_jaip_2020_05_003
crossref_primary_10_1007_BF03262132
crossref_primary_10_1159_000488050
crossref_primary_10_1007_s00405_023_08078_7
crossref_primary_10_1177_1753465816669662
crossref_primary_10_1016_j_pepo_2012_07_008
crossref_primary_10_1177_1559325820904799
crossref_primary_10_1002_lary_23649
crossref_primary_10_5604_01_3001_0054_0941
crossref_primary_10_3402_acmo_v3_26601
crossref_primary_10_1016_j_heliyon_2021_e08556
crossref_primary_10_4168_aair_2017_9_2_116
crossref_primary_10_1111_j_1365_2222_2011_03929_x
crossref_primary_10_1016_j_jaci_2019_01_053
crossref_primary_10_1016_j_reval_2014_12_007
crossref_primary_10_18311_jeoh_2024_36199
crossref_primary_10_1016_j_heliyon_2024_e39058
crossref_primary_10_1186_s13601_017_0159_6
crossref_primary_10_4168_aair_2015_7_2_158
crossref_primary_10_1016_j_anpede_2018_01_002
crossref_primary_10_3390_pharmacy8040183
crossref_primary_10_1016_j_waojou_2023_100849
crossref_primary_10_1080_02770903_2017_1326132
crossref_primary_10_47102_annals_acadmedsg_202076
crossref_primary_10_1016_j_anai_2024_10_019
crossref_primary_10_1111_cea_70137
crossref_primary_10_1177_1945892419883238
crossref_primary_10_1111_all_12988
crossref_primary_10_1016_j_anai_2014_08_015
crossref_primary_10_1016_j_bjorl_2017_01_002
crossref_primary_10_1080_03007995_2016_1240665
crossref_primary_10_1186_s12948_015_0029_5
crossref_primary_10_1038_s41598_024_54574_z
crossref_primary_10_1007_s00112_016_0063_5
crossref_primary_10_1186_2045_7022_2_13
crossref_primary_10_1007_s11882_013_0341_4
crossref_primary_10_1186_2045_7022_2_16
crossref_primary_10_1183_13993003_00437_2018
crossref_primary_10_3109_02770903_2015_1056350
crossref_primary_10_1111_pai_12562
crossref_primary_10_3389_fphar_2024_1417013
crossref_primary_10_1007_s11882_014_0422_z
crossref_primary_10_1016_j_arbres_2017_03_001
crossref_primary_10_36303_SAGP_0124
crossref_primary_10_1002_alr_22190
crossref_primary_10_4168_aair_2013_5_5_251
crossref_primary_10_2500_ajra_2012_26_3706
crossref_primary_10_1007_s40267_017_0381_2
crossref_primary_10_1159_000496938
crossref_primary_10_1177_00034894211008702
crossref_primary_10_1002_alr_22197
crossref_primary_10_1371_journal_pone_0090338
crossref_primary_10_3390_ijerph15071449
crossref_primary_10_1016_j_jaci_2020_07_007
crossref_primary_10_1186_s13063_019_3424_2
crossref_primary_10_1007_s11882_011_0185_8
crossref_primary_10_1186_s13223_018_0299_9
crossref_primary_10_1007_s00228_014_1767_x
crossref_primary_10_1186_s13223_015_0083_z
crossref_primary_10_1016_j_reval_2014_05_005
crossref_primary_10_1111_all_12760
crossref_primary_10_1186_1939_4551_7_6
crossref_primary_10_1016_j_jaci_2016_03_010
crossref_primary_10_1016_S1877_0320_11_70034_3
crossref_primary_10_1186_1939_4551_7_4
crossref_primary_10_1007_s40521_016_0076_2
crossref_primary_10_3389_fcimb_2023_1150043
crossref_primary_10_1142_S0192415X19500204
crossref_primary_10_1007_s11882_012_0288_x
crossref_primary_10_1016_j_ctim_2022_102804
crossref_primary_10_1007_s11882_012_0242_y
crossref_primary_10_1080_14656566_2024_2411009
crossref_primary_10_1016_j_jaci_2011_10_044
crossref_primary_10_1080_1744666X_2024_2373886
crossref_primary_10_25122_jml_2020_0015
crossref_primary_10_1111_fcp_12079
crossref_primary_10_4168_aair_2013_5_4_232
crossref_primary_10_1016_j_jaip_2017_05_028
crossref_primary_10_1177_00034894241304931
crossref_primary_10_1186_s13601_018_0227_6
crossref_primary_10_1186_s40413_015_0064_1
crossref_primary_10_1016_j_otc_2017_08_012
crossref_primary_10_1097_MOO_0000000000000045
crossref_primary_10_1016_j_jaci_2016_03_025
crossref_primary_10_1016_j_rmed_2018_01_020
crossref_primary_10_1002_clt2_12316
crossref_primary_10_1016_j_bjorl_2020_12_014
crossref_primary_10_1017_S0022215116000128
crossref_primary_10_1016_j_rmed_2015_05_010
crossref_primary_10_1111_all_12531
crossref_primary_10_1016_j_anai_2015_07_022
crossref_primary_10_1016_j_jaci_2013_05_032
crossref_primary_10_1016_j_anai_2020_06_032
crossref_primary_10_1007_s15007_019_1938_2
crossref_primary_10_1542_peds_2014_1641
crossref_primary_10_1007_s40267_016_0349_7
crossref_primary_10_1002_alr_23090
crossref_primary_10_1016_j_anai_2015_07_016
crossref_primary_10_1016_j_anl_2013_06_003
crossref_primary_10_1080_02770903_2017_1362428
crossref_primary_10_1016_j_waojou_2024_100926
crossref_primary_10_1002_alr_21905
crossref_primary_10_1007_s13318_025_00946_3
crossref_primary_10_1016_j_arbr_2018_12_020
crossref_primary_10_1136_bmjopen_2017_016326
crossref_primary_10_1096_fj_201902627R
crossref_primary_10_1111_all_12782
crossref_primary_10_1111_resp_14174
crossref_primary_10_1136_archdischild_2014_306300
crossref_primary_10_1016_j_genhosppsych_2012_09_009
crossref_primary_10_1016_j_reval_2014_10_005
crossref_primary_10_1016_j_fsc_2011_10_006
crossref_primary_10_1177_03946320110240S406
crossref_primary_10_1111_j_1398_9995_2012_02822_x
crossref_primary_10_1186_2045_7022_5_S4_P39
crossref_primary_10_1016_j_rmed_2018_03_014
crossref_primary_10_1097_WOX_0b013e3182784ee0
crossref_primary_10_2217_imt_2018_0051
crossref_primary_10_1016_j_reval_2014_10_003
crossref_primary_10_1007_s00405_017_4807_1
crossref_primary_10_1111_all_12791
crossref_primary_10_3390_pharmacy8020085
crossref_primary_10_1186_s13223_018_0268_3
crossref_primary_10_1016_j_wjorl_2020_12_001
crossref_primary_10_3109_00016489_2014_890739
crossref_primary_10_1111_all_13406
crossref_primary_10_1007_s10405_012_0584_0
crossref_primary_10_4168_aair_2015_7_1_83
crossref_primary_10_1186_s12890_021_01798_8
crossref_primary_10_1016_j_ctim_2019_102198
crossref_primary_10_1089_ped_2015_0519
crossref_primary_10_1111_cea_14212
crossref_primary_10_3109_02770903_2013_853082
crossref_primary_10_1007_s11010_017_2963_7
crossref_primary_10_3892_mmr_2016_6085
crossref_primary_10_4168_aair_2018_10_4_300
crossref_primary_10_1186_s12931_021_01766_0
crossref_primary_10_1586_1744666X_2015_1081814
crossref_primary_10_1007_s00060_017_5525_4
crossref_primary_10_1016_j_biopha_2018_11_073
crossref_primary_10_1002_clt2_12128
crossref_primary_10_1007_s12325_016_0347_0
crossref_primary_10_1016_j_molimm_2023_02_004
crossref_primary_10_1186_1471_2466_13_46
crossref_primary_10_2147_IJGM_S470949
crossref_primary_10_3892_etm_2017_4937
crossref_primary_10_1016_j_jaip_2020_08_025
crossref_primary_10_1111_j_1398_9995_2010_02530_x
crossref_primary_10_1111_all_12573
crossref_primary_10_1097_GH9_0000000000000480
crossref_primary_10_1007_s00106_012_2484_3
crossref_primary_10_1080_1744666X_2016_1237288
crossref_primary_10_1111_all_13429
crossref_primary_10_1111_coa_12171
crossref_primary_10_1016_j_iac_2015_12_008
crossref_primary_10_1080_17460441_2017_1257115
crossref_primary_10_4103_pm_pm_461_19
crossref_primary_10_1016_j_iac_2015_12_004
crossref_primary_10_1016_j_reval_2012_01_034
crossref_primary_10_1016_j_iac_2015_12_001
crossref_primary_10_1007_s40267_016_0305_6
crossref_primary_10_1016_j_ijporl_2019_109759
crossref_primary_10_1517_14740338_2016_1112786
crossref_primary_10_1016_j_anl_2019_05_005
crossref_primary_10_1016_j_mayocp_2017_01_001
crossref_primary_10_5144_0256_4947_2013_469
crossref_primary_10_1007_s40521_016_0073_5
crossref_primary_10_3389_fphar_2024_1350063
crossref_primary_10_1007_s40521_021_00280_4
crossref_primary_10_1097_MD_0000000000015247
crossref_primary_10_1111_all_12903
crossref_primary_10_2500_ajra_2012_26_3785
crossref_primary_10_1177_1945892419865097
crossref_primary_10_1097_MD_0000000000029871
crossref_primary_10_1177_039463201102400212
crossref_primary_10_1007_s00405_015_3832_1
crossref_primary_10_1007_s00405_018_5123_0
crossref_primary_10_2500_ajra_2012_26_3787
crossref_primary_10_1080_13543784_2016_1192124
crossref_primary_10_1016_j_anorl_2017_06_005
crossref_primary_10_1097_01_NPR_0000444647_43315_8c
crossref_primary_10_1517_17460441_2014_909403
crossref_primary_10_1016_j_iac_2011_02_004
crossref_primary_10_5662_wjm_v6_i4_200
crossref_primary_10_7759_cureus_40913
crossref_primary_10_1177_1945892419860646
crossref_primary_10_1007_s00106_012_2483_4
crossref_primary_10_4168_aair_2019_11_3_306
crossref_primary_10_1186_1745_9974_10_2
crossref_primary_10_1016_j_vaccine_2013_03_041
crossref_primary_10_1111_cea_14135
crossref_primary_10_1111_all_12917
crossref_primary_10_1002_alr_22118
crossref_primary_10_1186_s13223_017_0183_z
crossref_primary_10_1016_j_aller_2014_04_011
crossref_primary_10_1016_j_eujim_2022_102166
crossref_primary_10_1002_alr_21294
crossref_primary_10_1177_0145561319874310
crossref_primary_10_1007_s00405_015_3769_4
crossref_primary_10_1007_s00405_020_05837_8
crossref_primary_10_3892_etm_2017_4215
crossref_primary_10_1177_1945892420964408
crossref_primary_10_1111_j_1365_2125_2012_04222_x
crossref_primary_10_1007_s40521_018_0166_4
crossref_primary_10_1186_s13601_019_0252_0
crossref_primary_10_1016_j_aller_2019_06_013
crossref_primary_10_1371_journal_pone_0085802
crossref_primary_10_3389_falgy_2025_1600032
crossref_primary_10_1002_ppul_22912
crossref_primary_10_1111_pai_13717
crossref_primary_10_1016_j_aller_2019_06_011
crossref_primary_10_1016_j_jaip_2013_04_005
crossref_primary_10_2500_ajra_2012_26_3770
crossref_primary_10_1016_j_jaci_2015_04_047
crossref_primary_10_1089_tmj_2012_0020
crossref_primary_10_1016_j_ijthermalsci_2019_04_018
crossref_primary_10_1111_cea_13264
crossref_primary_10_1007_s15007_020_2551_0
crossref_primary_10_1016_j_ijporl_2013_07_019
crossref_primary_10_1155_2024_9692031
crossref_primary_10_1183_09031936_00014614
crossref_primary_10_1186_s13601_019_0243_1
crossref_primary_10_1097_DBP_0000000000001206
crossref_primary_10_3390_medsci6040114
crossref_primary_10_1016_j_anai_2011_07_014
crossref_primary_10_1002_alr_23259
crossref_primary_10_1007_s40629_017_0027_x
crossref_primary_10_1007_s40136_013_0013_x
crossref_primary_10_1016_j_intimp_2020_106603
crossref_primary_10_1016_j_jaip_2020_09_008
crossref_primary_10_1186_2046_4053_3_59
crossref_primary_10_1016_j_anorl_2017_07_003
crossref_primary_10_1164_rccm_202109_2205PP
crossref_primary_10_1016_j_conctc_2016_06_002
crossref_primary_10_2500_ajra_2014_28_4112
crossref_primary_10_1371_journal_pone_0103540
crossref_primary_10_1016_j_jaip_2015_06_019
crossref_primary_10_1016_j_jaip_2016_11_024
crossref_primary_10_1016_j_phymed_2018_06_044
crossref_primary_10_1517_14740338_2013_788148
crossref_primary_10_7759_cureus_46663
crossref_primary_10_2500_aap_2022_43_210113
crossref_primary_10_1097_ACI_0000000000000513
crossref_primary_10_1111_all_13807
crossref_primary_10_1111_all_13805
crossref_primary_10_1016_j_molimm_2020_04_009
crossref_primary_10_1177_0194599812461999
crossref_primary_10_1007_s12070_020_02008_3
crossref_primary_10_1186_s13601_016_0116_9
crossref_primary_10_1177_1945892419826509
crossref_primary_10_1111_all_12963
crossref_primary_10_1039_D4FO01079E
crossref_primary_10_1186_s40413_016_0133_0
crossref_primary_10_3389_fimmu_2021_723814
crossref_primary_10_1016_j_toxlet_2018_11_012
crossref_primary_10_1186_s13601_017_0150_2
crossref_primary_10_1186_s13223_017_0208_7
crossref_primary_10_1002_alr_22186
crossref_primary_10_1186_s43163_025_00845_z
crossref_primary_10_1007_s40521_016_0105_1
crossref_primary_10_1016_j_arbres_2012_12_001
crossref_primary_10_1016_j_jaip_2013_03_012
crossref_primary_10_1186_s12955_020_01659_8
crossref_primary_10_1177_1945892420912370
crossref_primary_10_1186_s12887_025_05541_8
crossref_primary_10_2147_JAA_S281439
crossref_primary_10_1155_2014_746846
crossref_primary_10_1016_j_jaci_2012_07_053
crossref_primary_10_1111_coa_12695
crossref_primary_10_1016_j_heliyon_2024_e29450
crossref_primary_10_2165_11209310_000000000_00000
crossref_primary_10_1007_s00405_011_1916_0
crossref_primary_10_1155_2013_861213
crossref_primary_10_1186_s12955_017_0621_0
crossref_primary_10_1097_ACI_0b013e32834cb994
crossref_primary_10_1111_all_14240
crossref_primary_10_1016_j_jpsychores_2015_08_009
crossref_primary_10_1186_2045_7022_3_7
crossref_primary_10_1186_1741_7015_12_71
crossref_primary_10_1185_03007995_2015_1094653
crossref_primary_10_1016_j_bjorl_2015_01_003
crossref_primary_10_1186_1916_0216_42_58
crossref_primary_10_1517_14740338_2016_1122755
crossref_primary_10_1016_j_ijheh_2016_11_012
crossref_primary_10_25259_IJMS_192_2022
crossref_primary_10_1007_s40521_020_00245_z
crossref_primary_10_2500_ajra_2017_31_4382
crossref_primary_10_1155_2020_6917185
crossref_primary_10_2500_ajra_2013_27_3856
crossref_primary_10_7705_biomedica_v38i3_3801
crossref_primary_10_3390_pharmaceutics15041195
crossref_primary_10_1111_all_13162
crossref_primary_10_1136_bmjopen_2014_006570
crossref_primary_10_1111_all_14013
crossref_primary_10_1186_s13601_015_0087_2
crossref_primary_10_1080_02770903_2021_1978480
crossref_primary_10_1016_j_waojou_2020_100106
crossref_primary_10_1183_13993003_02730_2021
crossref_primary_10_1159_000443273
crossref_primary_10_1016_j_biopha_2019_109675
crossref_primary_10_1155_2020_1847061
crossref_primary_10_1159_000512493
crossref_primary_10_3390_jpm13050835
crossref_primary_10_3390_medicina56090454
crossref_primary_10_1586_1744666X_2014_955476
crossref_primary_10_1177_20587392211016117
crossref_primary_10_3390_ijms21145010
crossref_primary_10_1002_alr_21695
crossref_primary_10_1016_j_reval_2019_06_006
crossref_primary_10_1186_s12889_024_18581_z
crossref_primary_10_1080_07448481_2018_1462822
crossref_primary_10_2217_imt_11_171
crossref_primary_10_1371_journal_pone_0147778
crossref_primary_10_1016_j_ijpharm_2019_03_040
crossref_primary_10_1016_j_ijporl_2016_01_010
crossref_primary_10_1016_j_joim_2017_12_010
crossref_primary_10_1136_bmjopen_2017_019462
crossref_primary_10_1007_s40521_018_0162_8
crossref_primary_10_1016_j_drudis_2015_07_010
crossref_primary_10_1007_s40521_020_00243_1
crossref_primary_10_1016_j_nano_2013_05_011
crossref_primary_10_1177_1945892419875086
crossref_primary_10_1007_s00060_014_0263_3
crossref_primary_10_1007_s00405_014_3350_6
crossref_primary_10_1186_s12931_016_0430_8
crossref_primary_10_1186_s13223_018_0314_1
crossref_primary_10_1586_1744666X_2014_945434
crossref_primary_10_1016_j_jaip_2012_07_001
crossref_primary_10_1016_j_reval_2017_03_003
crossref_primary_10_1002_alr_21689
crossref_primary_10_1517_14656566_2014_872241
crossref_primary_10_1002_alr_21449
crossref_primary_10_2217_imt_2019_0187
crossref_primary_10_1016_j_arbres_2018_09_001
crossref_primary_10_3892_etm_2016_3616
crossref_primary_10_3390_jcm9051483
crossref_primary_10_1016_j_jaip_2018_01_028
crossref_primary_10_1002_alr_23414
crossref_primary_10_1371_journal_pone_0059174
crossref_primary_10_1097_MD_0000000000018554
crossref_primary_10_1007_s40136_017_0170_4
crossref_primary_10_1007_s40267_014_0165_x
crossref_primary_10_1007_s11882_015_0570_9
crossref_primary_10_1016_j_anai_2015_10_025
crossref_primary_10_1016_j_reval_2019_07_007
crossref_primary_10_1111_j_1399_3038_2012_01323_x
crossref_primary_10_1159_000506862
crossref_primary_10_1016_j_bjorl_2024_101424
crossref_primary_10_1007_s00005_017_0498_y
crossref_primary_10_1155_2013_345217
crossref_primary_10_1016_j_intimp_2011_07_005
crossref_primary_10_1007_s15007_013_0351_5
crossref_primary_10_1155_2017_3054217
crossref_primary_10_2500_ajra_2013_27_3864
crossref_primary_10_3390_ijms20010213
crossref_primary_10_1016_j_cyto_2019_154880
crossref_primary_10_1016_j_ajo_2020_07_011
crossref_primary_10_2147_IJGM_S325969
crossref_primary_10_1007_s00405_011_1803_8
crossref_primary_10_1016_j_iac_2016_03_011
crossref_primary_10_1016_j_ebiom_2018_05_037
crossref_primary_10_3390_pathogens11010080
crossref_primary_10_1128_IAI_00934_17
crossref_primary_10_1007_s11596_014_1275_3
crossref_primary_10_1007_s40629_020_00133_7
crossref_primary_10_1007_s40629_022_00218_5
crossref_primary_10_1155_2016_7896081
crossref_primary_10_2147_JAA_S342495
crossref_primary_10_1017_S0022215121000967
crossref_primary_10_1111_cts_13455
crossref_primary_10_1038_s41572_020_00227_0
crossref_primary_10_1002_ohn_832
crossref_primary_10_1155_2020_2384596
crossref_primary_10_1016_j_alergo_2014_05_004
crossref_primary_10_1016_j_amjoto_2023_104135
crossref_primary_10_20538_1682_0363_2019_2_262_273
crossref_primary_10_1038_s41392_023_01344_4
crossref_primary_10_1089_acm_2016_0310
crossref_primary_10_1183_23120541_00015_2020
crossref_primary_10_1097_ACI_0000000000000375
crossref_primary_10_1371_journal_pone_0228533
crossref_primary_10_1186_s40413_016_0126_z
crossref_primary_10_1016_j_waojou_2021_100612
crossref_primary_10_4168_aair_2017_9_3_220
crossref_primary_10_1016_j_pedneo_2017_11_020
crossref_primary_10_1016_j_lfs_2019_116901
crossref_primary_10_3390_healthcare13080875
crossref_primary_10_1080_02770903_2019_1684517
crossref_primary_10_1016_S1877_0320_20_30479_6
crossref_primary_10_3389_fncel_2016_00169
crossref_primary_10_1080_14656566_2018_1543401
crossref_primary_10_1111_all_13316
crossref_primary_10_1111_all_13317
crossref_primary_10_1136_bjsports_2011_090812
crossref_primary_10_1155_2014_326980
crossref_primary_10_6000_1927_5951_2016_06_03_3
crossref_primary_10_1186_s13601_016_0099_6
crossref_primary_10_1016_S2095_4964_17_60353_4
crossref_primary_10_1183_13993003_01023_2019
crossref_primary_10_1177_2473974X211052955
crossref_primary_10_1159_000442353
crossref_primary_10_1097_MD_0000000000008032
crossref_primary_10_3389_fgene_2022_899923
crossref_primary_10_2500_ajra_2017_31_4418
crossref_primary_10_1183_13993003_00385_2015
crossref_primary_10_1016_j_arbr_2017_03_026
crossref_primary_10_1016_j_cellimm_2019_104035
crossref_primary_10_1177_0394632015621769
crossref_primary_10_1097_ACI_0b013e3283445852
crossref_primary_10_3892_mmr_2017_6215
crossref_primary_10_1016_j_arbres_2021_10_003
crossref_primary_10_1016_j_jaip_2019_11_008
crossref_primary_10_36290_der_2019_004
crossref_primary_10_1186_s13601_015_0061_z
crossref_primary_10_1016_j_reval_2024_104160
crossref_primary_10_1016_j_jaip_2014_01_009
crossref_primary_10_3389_fpubh_2024_1301095
crossref_primary_10_1007_s12070_014_0708_4
crossref_primary_10_1016_j_jaci_2012_01_047
crossref_primary_10_1111_all_14422
crossref_primary_10_1016_j_jaci_2017_03_050
crossref_primary_10_1007_s00405_016_3973_x
crossref_primary_10_4168_aair_2024_16_1_9
crossref_primary_10_1111_all_12009
crossref_primary_10_1016_j_aller_2012_03_004
crossref_primary_10_1016_j_jclinepi_2015_12_008
crossref_primary_10_1016_j_aller_2012_03_005
crossref_primary_10_1002_alr_21615
crossref_primary_10_1016_j_jaip_2014_01_006
crossref_primary_10_1097_ACI_0000000000000043
crossref_primary_10_1097_ACI_0000000000000062
crossref_primary_10_3390_ijms19030673
crossref_primary_10_4103_0972_6691_124391
crossref_primary_10_1111_pai_12066
crossref_primary_10_1007_s15006_014_0004_y
crossref_primary_10_1002_lary_26831
crossref_primary_10_1016_S1877_0320_11_70026_4
crossref_primary_10_1016_j_alergo_2017_02_003
crossref_primary_10_1016_j_alergo_2017_02_001
crossref_primary_10_1016_j_reval_2015_04_001
crossref_primary_10_1002_alr_21606
crossref_primary_10_3109_01480545_2012_682652
crossref_primary_10_3390_medicina54050083
crossref_primary_10_23736_S0022_4707_18_08556_0
crossref_primary_10_1513_AnnalsATS_201505_309ED
crossref_primary_10_1007_s00106_021_01115_z
crossref_primary_10_1016_j_iac_2011_05_002
crossref_primary_10_1186_s13601_019_0303_6
crossref_primary_10_4168_aair_2017_9_3_265
crossref_primary_10_1177_039463201202500313
crossref_primary_10_1038_s41533_018_0071_0
crossref_primary_10_1007_BF03262237
crossref_primary_10_1016_j_anai_2016_07_018
crossref_primary_10_1177_039463201202500318
crossref_primary_10_1007_s10735_013_9484_9
crossref_primary_10_2500_ajra_2011_25_3674
crossref_primary_10_1016_j_paed_2012_02_001
crossref_primary_10_1007_s40629_022_00241_6
crossref_primary_10_1517_14656566_2013_828693
crossref_primary_10_1016_j_jaci_2019_06_049
crossref_primary_10_1097_MD_0000000000022521
crossref_primary_10_1155_2019_6478102
crossref_primary_10_1016_j_reval_2018_10_006
crossref_primary_10_1111_pai_12260
crossref_primary_10_1097_MD_0000000000024943
crossref_primary_10_2147_JAA_S503477
crossref_primary_10_1016_j_iac_2011_05_009
crossref_primary_10_1155_2014_176597
crossref_primary_10_2217_imt_15_88
crossref_primary_10_1002_ebch_1865
crossref_primary_10_1111_pai_13332
crossref_primary_10_1155_2013_720879
crossref_primary_10_1111_all_13362
crossref_primary_10_3892_mmr_2018_9380
crossref_primary_10_1016_j_jconrel_2023_01_029
crossref_primary_10_1159_000499042
crossref_primary_10_2500_ajra_2015_29_4148
crossref_primary_10_1016_j_otc_2011_03_008
crossref_primary_10_1111_all_14215
crossref_primary_10_1111_cea_13884
crossref_primary_10_1155_2016_9471215
crossref_primary_10_1002_alr_21628
crossref_primary_10_1002_humu_23548
crossref_primary_10_1016_j_jaci_2014_06_034
crossref_primary_10_2196_63933
crossref_primary_10_1007_s40261_015_0267_9
crossref_primary_10_1186_s40733_015_0006_2
crossref_primary_10_1111_all_13370
crossref_primary_10_1111_all_12040
crossref_primary_10_1186_s13223_020_0416_4
crossref_primary_10_1016_j_alergo_2014_03_002
crossref_primary_10_1007_s00405_016_4128_9
crossref_primary_10_1186_s12890_016_0246_9
crossref_primary_10_1002_alr_22741
crossref_primary_10_1016_j_jamda_2015_12_017
crossref_primary_10_1002_alr_21654
crossref_primary_10_1016_j_otc_2011_03_001
crossref_primary_10_2217_imt_2022_0215
crossref_primary_10_1016_j_waojou_2021_100584
crossref_primary_10_1177_01945998211034724
crossref_primary_10_1002_alr_21657
crossref_primary_10_1056_NEJMcp1412282
crossref_primary_10_1016_j_alergo_2016_06_003
crossref_primary_10_1111_all_13141
crossref_primary_10_1183_13993003_01856_2015
crossref_primary_10_1159_000512561
crossref_primary_10_2500_ajra_2015_29_4164
crossref_primary_10_1080_03007995_2019_1681134
crossref_primary_10_1111_cea_12536
crossref_primary_10_1177_1945892420932768
crossref_primary_10_1186_s12948_017_0074_3
crossref_primary_10_1007_s11882_012_0330_z
crossref_primary_10_3390_jcm10143183
crossref_primary_10_1177_00034894231176327
crossref_primary_10_29262_ram_v65i4_525
crossref_primary_10_1007_s12016_016_8542_y
crossref_primary_10_4168_aair_2017_9_3_272
crossref_primary_10_2500_ajra_2015_29_4192
crossref_primary_10_3109_02770903_2015_1091005
crossref_primary_10_1186_1939_4551_6_5
crossref_primary_10_1007_s40521_016_0077_1
crossref_primary_10_1111_pai_12218
crossref_primary_10_1016_j_jaci_2017_05_040
crossref_primary_10_3892_etm_2012_798
crossref_primary_10_1080_03007995_2025_2452518
crossref_primary_10_1007_s11655_016_2453_x
crossref_primary_10_1016_j_ufug_2018_04_001
crossref_primary_10_1186_s13223_017_0209_6
crossref_primary_10_1002_alr_22087
crossref_primary_10_1016_j_imr_2023_100973
crossref_primary_10_1002_gin2_12008
crossref_primary_10_1186_s12887_018_1019_9
crossref_primary_10_1002_alr_22073
crossref_primary_10_1111_jcmm_12014
crossref_primary_10_1371_journal_pone_0175452
crossref_primary_10_2500_ajra_2015_29_4189
crossref_primary_10_1111_cea_13207
crossref_primary_10_1111_j_1600_065X_2011_01029_x
crossref_primary_10_1136_bmjopen_2018_026710
crossref_primary_10_1007_s00106_013_2709_0
crossref_primary_10_1111_cea_13686
crossref_primary_10_1136_bmjopen_2022_062435
crossref_primary_10_1055_a_1246_1288
crossref_primary_10_1007_s00405_018_5104_3
crossref_primary_10_1111_j_1398_9995_2011_02761_x
crossref_primary_10_1016_j_aller_2016_09_001
crossref_primary_10_1186_s40733_015_0008_0
crossref_primary_10_1016_j_otc_2023_09_003
crossref_primary_10_1111_j_1365_2222_2011_03935_x
crossref_primary_10_1097_MD_0000000000018931
crossref_primary_10_1016_j_jep_2022_115448
crossref_primary_10_1016_S1155_195X_12_57303_2
crossref_primary_10_1016_j_rmr_2013_08_006
crossref_primary_10_1016_j_clinthera_2017_10_006
crossref_primary_10_1016_j_pop_2016_04_006
crossref_primary_10_1159_000512920
crossref_primary_10_1097_MD_0000000000024121
crossref_primary_10_1038_ejcn_2012_197
crossref_primary_10_1080_14656566_2024_2307476
crossref_primary_10_1016_S1877_0320_11_70033_1
crossref_primary_10_1517_14656566_2011_600688
crossref_primary_10_1007_s40272_020_00419_x
crossref_primary_10_1007_s40521_017_0110_z
crossref_primary_10_1016_j_reval_2012_02_152
crossref_primary_10_2174_0113816128295952240306072100
crossref_primary_10_1038_s41598_020_79820_y
crossref_primary_10_1111_pai_12653
crossref_primary_10_1016_j_eurger_2014_07_013
crossref_primary_10_1186_s13223_015_0109_6
crossref_primary_10_3390_ijerph17010298
crossref_primary_10_1007_s40521_016_0075_3
crossref_primary_10_1155_2020_2975974
crossref_primary_10_7326_ANNALS_24_00363
crossref_primary_10_1097_MD_0000000000010394
crossref_primary_10_1016_j_anai_2014_11_001
crossref_primary_10_1038_npjpcrm_2016_33
crossref_primary_10_1177_039463201402700405
crossref_primary_10_1007_s12070_018_1273_z
crossref_primary_10_1097_MCP_0000000000000640
crossref_primary_10_1007_s11882_025_01195_9
crossref_primary_10_3390_nu13030934
crossref_primary_10_1016_j_jaip_2019_07_044
crossref_primary_10_1186_1477_7517_8_23
crossref_primary_10_1016_j_jaip_2019_06_003
crossref_primary_10_1016_j_jaip_2024_06_040
crossref_primary_10_3390_jcm8091338
crossref_primary_10_1016_j_anai_2019_05_020
crossref_primary_10_1093_qjmed_hcy259
crossref_primary_10_1016_j_otc_2023_08_009
crossref_primary_10_1186_s13020_019_0272_7
crossref_primary_10_1016_j_ijpharm_2019_118911
crossref_primary_10_1007_s00405_013_2875_4
crossref_primary_10_1097_ACI_0b013e32835c1b73
crossref_primary_10_1007_s00405_017_4785_3
crossref_primary_10_1080_07853890_2023_2287188
crossref_primary_10_1016_j_gene_2012_06_066
crossref_primary_10_1177_014556131809700803
crossref_primary_10_1002_clt2_12006
crossref_primary_10_1016_j_intimp_2017_04_005
crossref_primary_10_2500_ajra_2012_26_3836
crossref_primary_10_1586_17512433_2016_1148598
crossref_primary_10_1007_s00431_019_03444_2
crossref_primary_10_1111_all_12686
crossref_primary_10_3389_fmed_2021_731254
crossref_primary_10_1186_s13223_019_0368_8
crossref_primary_10_1111_cea_12386
crossref_primary_10_1111_cea_13234
crossref_primary_10_1016_j_rmr_2019_08_003
crossref_primary_10_1016_j_alergo_2016_04_002
crossref_primary_10_1155_2020_8363027
crossref_primary_10_1517_14656566_2015_1020789
crossref_primary_10_1177_1755738017719096
crossref_primary_10_1016_j_rmr_2024_07_005
crossref_primary_10_1111_all_12694
crossref_primary_10_1155_2020_9248479
crossref_primary_10_1586_1744666X_2013_828876
crossref_primary_10_1080_14740338_2016_1221399
crossref_primary_10_4168_aair_2023_15_6_725
crossref_primary_10_1111_coa_13143
crossref_primary_10_1155_2020_4176082
crossref_primary_10_1111_j_1399_3038_2012_01298_x
crossref_primary_10_1002_ped4_12146
crossref_primary_10_1038_pr_2013_142
crossref_primary_10_1111_all_16387
crossref_primary_10_1183_16000617_0056_2018
crossref_primary_10_1016_j_intimp_2023_110623
crossref_primary_10_1111_resp_12116
crossref_primary_10_1080_1744666X_2016_1200467
crossref_primary_10_1016_j_jclinepi_2016_09_009
crossref_primary_10_1002_alr_23578
crossref_primary_10_20867_thm_15_1_1
crossref_primary_10_3109_02770903_2013_840789
crossref_primary_10_2147_JAA_S357288
crossref_primary_10_1016_j_anai_2019_08_010
crossref_primary_10_1007_s40267_013_0106_0
crossref_primary_10_1007_s12070_025_05793_x
crossref_primary_10_32448_entupdates_459007
crossref_primary_10_1002_alr_21381
crossref_primary_10_1017_S0022215113000170
crossref_primary_10_1055_a_2194_6914
crossref_primary_10_1002_alr_21389
crossref_primary_10_1111_j_1399_3038_2011_01182_x
crossref_primary_10_1002_alr_21141
crossref_primary_10_1016_j_aller_2015_05_004
crossref_primary_10_1016_j_bjorl_2024_101500
crossref_primary_10_1111_cea_13164
crossref_primary_10_1177_1945892418825094
crossref_primary_10_3389_fnut_2022_821900
crossref_primary_10_1016_j_bjorl_2015_11_009
crossref_primary_10_1002_jat_1726
crossref_primary_10_1186_s12944_023_01825_z
crossref_primary_10_1186_s13601_016_0137_4
crossref_primary_10_2217_imt_2015_0017
crossref_primary_10_1186_s13020_025_01120_2
crossref_primary_10_2500_ajra_2016_30_4305
crossref_primary_10_1007_s40521_014_0013_1
crossref_primary_10_1177_1945892418764966
crossref_primary_10_1177_1945892418764964
crossref_primary_10_1007_s12070_018_1500_7
crossref_primary_10_1016_j_jaci_2016_06_060
crossref_primary_10_1038_npjpcrm_2015_82
crossref_primary_10_1016_j_jped_2020_08_005
crossref_primary_10_1111_ddg_12089
crossref_primary_10_1016_j_jaci_2016_05_029
crossref_primary_10_2147_JAA_S461295
crossref_primary_10_1186_2045_7022_4_15
crossref_primary_10_2217_imt_2019_0009
crossref_primary_10_1586_17476348_2015_1000866
crossref_primary_10_1007_s11882_018_0781_y
crossref_primary_10_1111_j_1399_3038_2012_01322_x
crossref_primary_10_1186_s12906_017_1988_5
crossref_primary_10_2500_ajra_2016_30_4316
crossref_primary_10_2217_imt_2015_0027
crossref_primary_10_1002_kjm2_12918
crossref_primary_10_1002_kjm2_12916
crossref_primary_10_1097_MD_0000000000020711
crossref_primary_10_1186_s12881_017_0379_6
crossref_primary_10_1111_j_1398_9995_2011_02590_x
crossref_primary_10_1111_j_1472_9733_2011_01158_x
crossref_primary_10_1016_j_rmed_2012_02_013
crossref_primary_10_5812_ijp_83995
crossref_primary_10_1016_j_aforl_2017_02_005
crossref_primary_10_1016_j_jaci_2016_06_059
crossref_primary_10_1007_s12603_016_0804_0
crossref_primary_10_1016_j_iac_2018_01_014
crossref_primary_10_1016_j_micpath_2021_105272
crossref_primary_10_1159_000450751
crossref_primary_10_1016_j_anai_2020_11_016
crossref_primary_10_1016_j_otc_2017_08_004
crossref_primary_10_1016_j_clim_2020_108383
crossref_primary_10_1016_j_aforl_2017_03_009
crossref_primary_10_1016_j_jaci_2020_07_036
crossref_primary_10_1515_jbcr_2016_0021
crossref_primary_10_1007_s15012_014_1745_0
crossref_primary_10_1155_2012_521780
crossref_primary_10_4102_safp_v65i1_5806
crossref_primary_10_2500_ajra_2013_27_3937
crossref_primary_10_4081_mrm_2021_775
crossref_primary_10_1111_pai_12926
crossref_primary_10_3109_02770903_2013_822081
crossref_primary_10_1002_lary_28433
crossref_primary_10_1016_j_jaci_2011_09_005
crossref_primary_10_1002_clt2_12185
crossref_primary_10_1007_s00106_011_2294_z
crossref_primary_10_1007_s12070_021_02773_9
crossref_primary_10_1016_j_heliyon_2024_e32756
crossref_primary_10_4168_aair_2017_9_5_446
crossref_primary_10_1017_S0022215117001657
crossref_primary_10_1155_2015_214846
crossref_primary_10_1016_j_jconrel_2014_12_040
crossref_primary_10_1016_j_reval_2011_01_027
crossref_primary_10_1186_s12890_021_01410_z
crossref_primary_10_1186_s13601_019_0242_2
crossref_primary_10_1016_j_jaci_2014_01_042
crossref_primary_10_1186_s13601_017_0173_8
crossref_primary_10_1002_clt2_70017
crossref_primary_10_1186_2045_7022_4_7
crossref_primary_10_1016_j_compbiomed_2023_107544
crossref_primary_10_1016_j_coi_2011_07_015
crossref_primary_10_1007_s10453_016_9469_8
crossref_primary_10_1159_000477727
crossref_primary_10_1186_s12889_024_20561_2
crossref_primary_10_1111_cea_13192
crossref_primary_10_1186_1710_1492_9_32
crossref_primary_10_2500_ajra_2016_30_4352
crossref_primary_10_1016_j_reval_2011_01_015
crossref_primary_10_1155_2020_6760436
crossref_primary_10_1186_s13223_016_0119_z
crossref_primary_10_1007_s40136_013_0010_0
crossref_primary_10_1038_s41370_021_00304_w
crossref_primary_10_2500_ajra_2014_28_4013
crossref_primary_10_1111_all_13701
crossref_primary_10_1586_eci_11_87
crossref_primary_10_1016_j_reprotox_2011_06_120
crossref_primary_10_1097_ACI_0000000000000414
crossref_primary_10_1186_s12948_018_0092_9
crossref_primary_10_1016_j_jaci_2013_08_029
crossref_primary_10_1080_1744666X_2022_2089654
crossref_primary_10_1016_j_rmed_2020_105949
crossref_primary_10_1016_j_jaci_2018_08_049
crossref_primary_10_1097_MD_0000000000020911
crossref_primary_10_1038_pr_2014_151
crossref_primary_10_1177_0009922814533590
crossref_primary_10_1016_j_jaip_2025_04_060
crossref_primary_10_2500_ajra_2013_27_3965
crossref_primary_10_1016_j_jaip_2020_05_020
crossref_primary_10_1016_j_ijporl_2015_02_002
crossref_primary_10_3389_fpubh_2021_749388
crossref_primary_10_2500_ajra_2013_27_3968
crossref_primary_10_4168_aair_2018_10_2_182
crossref_primary_10_29262_ram_v71i1_1263
crossref_primary_10_4103_pm_pm_513_20
crossref_primary_10_33590_emj_10314632
crossref_primary_10_1371_journal_pone_0283246
crossref_primary_10_2147_JAA_S374346
crossref_primary_10_1007_s40521_016_0092_2
crossref_primary_10_1586_1744666X_2015_1086645
crossref_primary_10_1183_13993003_01084_2015
crossref_primary_10_1586_1744666X_2016_1144473
crossref_primary_10_1080_02770903_2016_1247168
crossref_primary_10_1097_ACI_0b013e32834c2286
crossref_primary_10_2500_ajra_2014_28_4035
crossref_primary_10_1177_0300060518786905
crossref_primary_10_1016_j_jaci_2010_11_032
crossref_primary_10_1097_ACI_0b013e32835e8b94
crossref_primary_10_1016_j_ijporl_2018_12_019
crossref_primary_10_1016_j_imlet_2020_08_002
crossref_primary_10_1159_000358489
crossref_primary_10_1002_ppul_23264
crossref_primary_10_4168_aair_2019_11_5_655
crossref_primary_10_1016_j_ijheh_2015_12_001
crossref_primary_10_1080_00325481_2017_1333384
crossref_primary_10_2500_ajra_2013_27_3944
crossref_primary_10_1007_s40267_014_0131_7
crossref_primary_10_1111_ajo_12673
crossref_primary_10_1016_j_waojou_2020_100466
crossref_primary_10_12688_f1000research_15367_1
crossref_primary_10_2500_ajra_2014_28_4066
crossref_primary_10_2500_ajra_2013_27_3946
crossref_primary_10_1517_14728214_2012_746312
crossref_primary_10_1016_j_waojou_2020_100461
crossref_primary_10_1080_1744666X_2023_2214729
crossref_primary_10_3109_02770903_2015_1054403
crossref_primary_10_1517_14656566_2016_1145661
crossref_primary_10_1016_j_jaci_2010_11_049
crossref_primary_10_1016_j_aller_2015_03_001
crossref_primary_10_1097_ACI_0000000000000204
crossref_primary_10_1016_j_jaci_2017_01_049
crossref_primary_10_3389_fphar_2024_1340554
crossref_primary_10_1016_j_waojou_2025_101117
crossref_primary_10_1016_j_gene_2013_03_088
crossref_primary_10_2500_ajra_2016_30_4397
crossref_primary_10_1093_intimm_dxv055
crossref_primary_10_1186_s12889_023_16607_6
crossref_primary_10_2500_ajra_2013_27_3957
crossref_primary_10_1007_s15007_017_1433_6
crossref_primary_10_1016_j_anai_2016_12_011
crossref_primary_10_2196_16642
crossref_primary_10_5935_1808_8694_20130067
crossref_primary_10_1186_s13063_015_0707_0
crossref_primary_10_1177_0194599819832277
crossref_primary_10_1517_14740338_2011_604029
crossref_primary_10_1097_ACI_0b013e32834c229e
crossref_primary_10_1007_s00106_013_2700_9
crossref_primary_10_1007_s15007_013_0065_8
crossref_primary_10_1097_ACI_0000000000000456
crossref_primary_10_1186_s13601_019_0279_2
crossref_primary_10_3390_ijerph17218207
crossref_primary_10_1016_j_cyto_2022_156027
crossref_primary_10_1016_j_jclinepi_2015_11_017
crossref_primary_10_2500_ar_2016_7_0176
crossref_primary_10_1186_s13063_018_3151_0
crossref_primary_10_1007_s40629_019_00110_9
crossref_primary_10_1186_1465_9921_13_50
crossref_primary_10_1097_ACI_0b013e3283457ab0
crossref_primary_10_1016_j_jaip_2021_10_001
crossref_primary_10_1186_2049_6958_7_49
crossref_primary_10_1177_0003489418812902
crossref_primary_10_1016_j_ijporl_2017_04_040
crossref_primary_10_1016_j_pop_2013_10_005
crossref_primary_10_1186_s13223_021_00614_6
crossref_primary_10_2500_ar_2016_7_0186
crossref_primary_10_1016_j_jaci_2013_09_004
crossref_primary_10_1016_j_jaip_2014_02_001
crossref_primary_10_2217_imt_2019_0051
crossref_primary_10_2500_ar_2016_7_0185
crossref_primary_10_1002_lio2_645
crossref_primary_10_1016_j_imbio_2012_11_006
crossref_primary_10_3109_02770903_2011_604886
crossref_primary_10_1002_alr_23521
crossref_primary_10_1007_s11356_020_08709_0
crossref_primary_10_1007_s11356_022_19897_2
crossref_primary_10_1080_14712598_2025_2531035
crossref_primary_10_1136_dtb_2013_1_0166
crossref_primary_10_1007_s40267_015_0254_5
crossref_primary_10_1016_j_joim_2021_01_012
crossref_primary_10_1016_j_reval_2013_07_003
crossref_primary_10_1016_j_zefq_2019_06_001
crossref_primary_10_1136_acupmed_2016_011354
crossref_primary_10_1089_ped_2014_0344
crossref_primary_10_1016_j_aller_2018_01_001
crossref_primary_10_1080_00325481_2015_1016386
crossref_primary_10_1080_24745332_2017_1410456
crossref_primary_10_1016_j_anai_2023_07_019
crossref_primary_10_1016_j_iac_2014_09_003
crossref_primary_10_1111_all_13098
crossref_primary_10_1097_01_NPR_0000406485_59758_a8
crossref_primary_10_1111_j_1398_9995_2012_02861_x
crossref_primary_10_1002_alr_21370
crossref_primary_10_1186_s12948_021_00158_5
crossref_primary_10_1097_MD_0000000000011812
crossref_primary_10_1038_s41598_023_46869_4
crossref_primary_10_1016_j_jaci_2014_03_019
crossref_primary_10_1016_j_cyto_2019_02_008
crossref_primary_10_1186_s12948_015_0023_y
crossref_primary_10_3390_ph18030326
crossref_primary_10_1016_j_jaci_2012_01_077
crossref_primary_10_1016_j_jaip_2022_07_020
crossref_primary_10_1016_S1877_0320_11_70028_8
crossref_primary_10_1007_s40521_014_0042_9
crossref_primary_10_1111_cea_12938
crossref_primary_10_1016_j_jaci_2010_11_018
crossref_primary_10_1007_s15007_022_5665_8
crossref_primary_10_1016_j_anpedi_2017_10_014
crossref_primary_10_1016_j_intimp_2013_02_009
crossref_primary_10_2500_ajra_2017_31_4434
crossref_primary_10_1016_j_otpol_2013_12_003
crossref_primary_10_1002_alr_22217
crossref_primary_10_1097_ACI_0000000000000495
crossref_primary_10_1002_alr_22219
crossref_primary_10_1155_2012_212867
Cites_doi 10.1111/j.1398-9995.2007.01620.x
10.1034/j.1398-9995.2003.00076.x
10.1067/mai.2001.118891
10.1111/j.1398-9995.2008.01642.x
10.1164/rccm.200602-197ST
10.4104/pcrj.2009.00028
10.1136/bmj.39490.551019.BE
10.1136/bmj.39489.470347.AD
10.1016/j.jaci.2008.06.003
10.1186/1478-4505-4-19
10.1111/j.1398-9995.2007.01560.x
10.1016/S0140-6736(09)60787-X
10.1111/j.1398-9995.2008.01884.x
10.1111/j.1365-2222.2007.02888.x
10.1186/1478-4505-4-28
10.1111/j.1398-9995.2006.01144.x
10.1016/j.pcrj.2005.11.002
10.1136/bmj.39493.646875.AE
10.1111/j.1398-9995.2009.01973.x
10.1111/j.1398-9995.2003.00468.x
10.1111/j.1398-9995.2009.02325.x
ContentType Journal Article
Contributor Dykewicz, M S
Bateman, E
Denburg, J
Chavannes, N H
Costa, D J
Pawankar, R
Yusuf, O
Demoly, P
Marshall, G
Nelson, H S
Vandenplas, O
Lee, B W
Bousquet, P J
Potter, P
Rabe, K
Boulet, L P
Rosenwasser, L
Toskala, E
El Gamal, Y
Mullol, J
Fokkens, W J
Kuna, P
Cruz, A
De Blay, F
Camargos, P
Larenas, D
Baker, A
Price, D
Ameille, J
Ben Kheder, A
Okamoto, Y
Ryan, D
Yawn, B
Bachert, C
Chuchalin, A
Le, L
Yorgancioglu, A
Bush, A
Cox, L
Dahl, R
Cazzola, M
Li, J
Wickman, M
Ivancevic, J C
Valiulis, A
Douagui, H
Kaliner, M
Kalayci, O
Martinez, F D
Custovic, A
Humbert, M
Chan, Yeung M
Niggemann, B
Shaik, A
Simons, F E R
Bouchard, J
Agache, I
Valovirta, E
Zitt, M
Papadopoulos, N
Holgate, S
Fukuda, T
Lockey, R
Malling, H Y
Mohammad, Y
Scadding, G
Kim, Y Y
Park, H S
Van Weel, C
Chen, Y C
O'Hehir, R
Sanchez Borges, M
Calderon, M
Dokic, D
Wang, D Y
Lipworth, B
Carlsen, K H
Rodríguez-Pérez, N
Contributor_xml – sequence: 1
  givenname: I
  surname: Agache
  fullname: Agache, I
– sequence: 2
  givenname: J
  surname: Ameille
  fullname: Ameille, J
– sequence: 3
  givenname: C
  surname: Bachert
  fullname: Bachert, C
– sequence: 4
  givenname: A
  surname: Baker
  fullname: Baker, A
– sequence: 5
  givenname: E
  surname: Bateman
  fullname: Bateman, E
– sequence: 6
  givenname: A
  surname: Ben Kheder
  fullname: Ben Kheder, A
– sequence: 7
  givenname: J
  surname: Bouchard
  fullname: Bouchard, J
– sequence: 8
  givenname: L P
  surname: Boulet
  fullname: Boulet, L P
– sequence: 9
  givenname: P J
  surname: Bousquet
  fullname: Bousquet, P J
– sequence: 10
  givenname: A
  surname: Bush
  fullname: Bush, A
– sequence: 11
  givenname: M
  surname: Calderon
  fullname: Calderon, M
– sequence: 12
  givenname: P
  surname: Camargos
  fullname: Camargos, P
– sequence: 13
  givenname: K H
  surname: Carlsen
  fullname: Carlsen, K H
– sequence: 14
  givenname: M
  surname: Cazzola
  fullname: Cazzola, M
– sequence: 15
  givenname: Yeung M
  surname: Chan
  fullname: Chan, Yeung M
– sequence: 16
  givenname: N H
  surname: Chavannes
  fullname: Chavannes, N H
– sequence: 17
  givenname: Y C
  surname: Chen
  fullname: Chen, Y C
– sequence: 18
  givenname: A
  surname: Chuchalin
  fullname: Chuchalin, A
– sequence: 19
  givenname: D J
  surname: Costa
  fullname: Costa, D J
– sequence: 20
  givenname: L
  surname: Cox
  fullname: Cox, L
– sequence: 21
  givenname: A
  surname: Cruz
  fullname: Cruz, A
– sequence: 22
  givenname: A
  surname: Custovic
  fullname: Custovic, A
– sequence: 23
  givenname: R
  surname: Dahl
  fullname: Dahl, R
– sequence: 24
  givenname: F
  surname: De Blay
  fullname: De Blay, F
– sequence: 25
  givenname: P
  surname: Demoly
  fullname: Demoly, P
– sequence: 26
  givenname: J
  surname: Denburg
  fullname: Denburg, J
– sequence: 27
  givenname: D
  surname: Dokic
  fullname: Dokic, D
– sequence: 28
  givenname: H
  surname: Douagui
  fullname: Douagui, H
– sequence: 29
  givenname: M S
  surname: Dykewicz
  fullname: Dykewicz, M S
– sequence: 30
  givenname: Y
  surname: El Gamal
  fullname: El Gamal, Y
– sequence: 31
  givenname: W J
  surname: Fokkens
  fullname: Fokkens, W J
– sequence: 32
  givenname: T
  surname: Fukuda
  fullname: Fukuda, T
– sequence: 33
  givenname: S
  surname: Holgate
  fullname: Holgate, S
– sequence: 34
  givenname: M
  surname: Humbert
  fullname: Humbert, M
– sequence: 35
  givenname: J C
  surname: Ivancevic
  fullname: Ivancevic, J C
– sequence: 36
  givenname: O
  surname: Kalayci
  fullname: Kalayci, O
– sequence: 37
  givenname: M
  surname: Kaliner
  fullname: Kaliner, M
– sequence: 38
  givenname: Y Y
  surname: Kim
  fullname: Kim, Y Y
– sequence: 39
  givenname: P
  surname: Kuna
  fullname: Kuna, P
– sequence: 40
  givenname: D
  surname: Larenas
  fullname: Larenas, D
– sequence: 41
  givenname: L
  surname: Le
  fullname: Le, L
– sequence: 42
  givenname: B W
  surname: Lee
  fullname: Lee, B W
– sequence: 43
  givenname: J
  surname: Li
  fullname: Li, J
– sequence: 44
  givenname: B
  surname: Lipworth
  fullname: Lipworth, B
– sequence: 45
  givenname: R
  surname: Lockey
  fullname: Lockey, R
– sequence: 46
  givenname: H Y
  surname: Malling
  fullname: Malling, H Y
– sequence: 47
  givenname: G
  surname: Marshall
  fullname: Marshall, G
– sequence: 48
  givenname: F D
  surname: Martinez
  fullname: Martinez, F D
– sequence: 49
  givenname: Y
  surname: Mohammad
  fullname: Mohammad, Y
– sequence: 50
  givenname: J
  surname: Mullol
  fullname: Mullol, J
– sequence: 51
  givenname: H S
  surname: Nelson
  fullname: Nelson, H S
– sequence: 52
  givenname: B
  surname: Niggemann
  fullname: Niggemann, B
– sequence: 53
  givenname: R
  surname: O'Hehir
  fullname: O'Hehir, R
– sequence: 54
  givenname: Y
  surname: Okamoto
  fullname: Okamoto, Y
– sequence: 55
  givenname: N
  surname: Papadopoulos
  fullname: Papadopoulos, N
– sequence: 56
  givenname: H S
  surname: Park
  fullname: Park, H S
– sequence: 57
  givenname: R
  surname: Pawankar
  fullname: Pawankar, R
– sequence: 58
  givenname: P
  surname: Potter
  fullname: Potter, P
– sequence: 59
  givenname: D
  surname: Price
  fullname: Price, D
– sequence: 60
  givenname: K
  surname: Rabe
  fullname: Rabe, K
– sequence: 61
  givenname: N
  surname: Rodríguez-Pérez
  fullname: Rodríguez-Pérez, N
– sequence: 62
  givenname: L
  surname: Rosenwasser
  fullname: Rosenwasser, L
– sequence: 63
  givenname: D
  surname: Ryan
  fullname: Ryan, D
– sequence: 64
  givenname: M
  surname: Sanchez Borges
  fullname: Sanchez Borges, M
– sequence: 65
  givenname: G
  surname: Scadding
  fullname: Scadding, G
– sequence: 66
  givenname: A
  surname: Shaik
  fullname: Shaik, A
– sequence: 67
  givenname: F E R
  surname: Simons
  fullname: Simons, F E R
– sequence: 68
  givenname: E
  surname: Toskala
  fullname: Toskala, E
– sequence: 69
  givenname: A
  surname: Valiulis
  fullname: Valiulis, A
– sequence: 70
  givenname: E
  surname: Valovirta
  fullname: Valovirta, E
– sequence: 71
  givenname: C
  surname: Van Weel
  fullname: Van Weel, C
– sequence: 72
  givenname: O
  surname: Vandenplas
  fullname: Vandenplas, O
– sequence: 73
  givenname: D Y
  surname: Wang
  fullname: Wang, D Y
– sequence: 74
  givenname: M
  surname: Wickman
  fullname: Wickman, M
– sequence: 75
  givenname: B
  surname: Yawn
  fullname: Yawn, B
– sequence: 76
  givenname: A
  surname: Yorgancioglu
  fullname: Yorgancioglu, A
– sequence: 77
  givenname: O
  surname: Yusuf
  fullname: Yusuf, O
– sequence: 78
  givenname: M
  surname: Zitt
  fullname: Zitt, M
Copyright 2010 American Academy of Allergy, Asthma & Immunology
American Academy of Allergy, Asthma & Immunology
2015 INIST-CNRS
Copyright (c) 2010 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.
Copyright Elsevier Limited Sep 2010
Copyright_xml – notice: 2010 American Academy of Allergy, Asthma & Immunology
– notice: American Academy of Allergy, Asthma & Immunology
– notice: 2015 INIST-CNRS
– notice: Copyright (c) 2010 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.
– notice: Copyright Elsevier Limited Sep 2010
CorporateAuthor Grading of Recommendations Assessment, Development and Evaluation Working Group
Global Allergy and Asthma European Network
CorporateAuthor_xml – name: Global Allergy and Asthma European Network
– name: Grading of Recommendations Assessment, Development and Evaluation Working Group
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7SS
7T5
H94
K9.
NAPCQ
7X8
DOI 10.1016/j.jaci.2010.06.047
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Entomology Abstracts (Full archive)
Immunology Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Nursing and Allied Health Premium
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Entomology Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
Immunology Abstracts
MEDLINE - Academic
DatabaseTitleList

AIDS and Cancer Research Abstracts
MEDLINE
Entomology Abstracts
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1097-6825
EndPage 476
ExternalDocumentID 3241196771
20816182
23238968
10_1016_j_jaci_2010_06_047
S0091674910010572
1_s2_0_S0091674910010572
Genre Research Support, Non-U.S. Gov't
Journal Article
Practice Guideline
GeographicLocations Ontario Canada
Netherlands
Manitoba Canada
Belgium
United Kingdom--UK
Japan
China
Denmark
Brazil
Italy
South Africa
France
GeographicLocations_xml – name: South Africa
– name: Ontario Canada
– name: Netherlands
– name: United Kingdom--UK
– name: Japan
– name: Italy
– name: Denmark
– name: China
– name: Manitoba Canada
– name: Belgium
– name: France
– name: Brazil
GrantInformation_xml – fundername: Ansell, Bayer Schering, DST, Fujisawa, HAL, Henkel, Kryolan, Leti, Merck Sharp & Dohme, Novartis, Procter & Gamble, Sanofi-Aventis, Schering Plough, Stallergenes and UCB Pharma
– fundername: Allmiral, ALK, AstraZeneca, Chiesi Farmaceutici, Faes Pharma, GlaxoSmithKline, Meda, Merck Sharp and Dohme, Mundifarma, Novartis, Nycomed-Altana, Roche, Sanofi-Aventis, Stallergènes, Schering- Plough, Teva, UCB and Uriach
– fundername: Allergopharma, Allmiral, Alcon, Crucell, Hal, Merck Sharp & Dome, Novartis, Stallargènes and UCB
– fundername: Abello, ALK, FAES (Spain), GlaxoSmithKline, Grünenthal (Venezuela), Lofarma (Italy), Merk Serono, MSD, Novartis, Phoenix (Argentina), Sanofi-Aventis, Schering-Plough, and Uriach (Spain)
– fundername: AstraZeneca, GlaxoSmithKline, Merck Banyu, Novartis, Schering Plough, Kyorin, Otsuka, and Taisho
– fundername: European Commission Framework Programme
  grantid: FOOD-CT-2004-506378
– fundername: Boehringer Ingelheim
– fundername: ALK, Almirall, AstraZeneca, GlaxoSmithKline, Menarini, Merck Sharp & Dohme, Novartis, Nycomed, Phadia, Schering-Plough, Sigma Tau and Stallergens
– fundername: A. Menarini, Alcon, Alk-Abellò, Almirall, Anallergo, AstraZeneca, Biofutura Pharma, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, Lofarma, Merck Sharp & Dome, Novartis, Nycomed, Pfizer, Phadia, Schering Plough, SigmaTau, Stallergenes, UCB Pharma, Uriach and Valeas
– fundername: GlaxoSmithKline and i3 Research
– fundername: Medical Research Council
  grantid: G0800766
– fundername: Medical Research Council
  grantid: G19/34
GroupedDBID ---
--K
--M
-~X
.1-
.55
.FO
.GJ
.XZ
.~1
0R~
1B1
1P~
1RT
1~.
1~5
354
3O-
4.4
457
4G.
53G
5GY
5RE
5VS
7-5
71M
8F7
8FE
8FH
8P~
9JM
AAAJQ
AABNK
AAEDT
AAEDW
AAFWJ
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AARKO
AATTM
AAXKI
AAXUO
AAYWO
ABBQC
ABFNM
ABJNI
ABLJU
ABMAC
ABMZM
ABOCM
ABWVN
ABXDB
ACDAQ
ACGFO
ACGFS
ACIEU
ACLOT
ACPRK
ACRLP
ACRPL
ACVFH
ADBBV
ADCNI
ADEZE
ADFRT
ADMUD
ADNMO
ADVLN
ADXHL
AEBSH
AEIPS
AEKER
AENEX
AEUPX
AFFNX
AFJKZ
AFPUW
AFRAH
AFRHN
AFTJW
AFXIZ
AGEKW
AGHFR
AGQPQ
AGUBO
AGYEJ
AHHHB
AHMBA
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
APXCP
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
BNPGV
BPHCQ
BVXVI
C45
CAG
CJTIS
COF
CS3
DU5
EBS
EFJIC
EFKBS
EFLBG
EJD
EO8
EO9
EP2
EP3
EX3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
GBLVA
HDU
HMK
HMO
HVGLF
HZ~
IHE
J1W
J5H
K-O
KOM
L7B
LK8
LUGTX
M27
M41
MO0
N4W
N9A
O-L
O9-
O9~
OAUVE
OBH
ODZKP
OHH
OHT
OK0
OK1
OVD
OZT
P-8
P-9
P2P
PC.
PQQKQ
PROAC
Q38
R2-
ROL
RPZ
SAE
SCC
SDF
SDG
SDP
SEL
SES
SEW
SJN
SPCBC
SSH
SSI
SSZ
T5K
TEORI
TWZ
UGJ
UNMZH
UV1
WH7
WOW
WUQ
X7M
XFW
YOC
YQI
YQJ
Z5R
ZGI
ZXP
ZY1
~02
~G-
~HD
~KM
AACTN
RIG
9DU
AAYXX
CITATION
AGCQF
AGRNS
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7SS
7T5
H94
K9.
NAPCQ
7X8
ID FETCH-LOGICAL-c617t-6a84db6967e0b4d48df03745b4590ff0a6ccea6552eae78c3b1976e3ca08a8933
ISICitedReferencesCount 1208
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000281512500008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 0091-6749
1097-6825
IngestDate Sun Sep 28 07:06:36 EDT 2025
Wed Oct 01 17:04:11 EDT 2025
Tue Oct 07 06:18:01 EDT 2025
Mon Jul 21 06:01:16 EDT 2025
Mon Jul 21 09:15:08 EDT 2025
Tue Nov 18 22:19:08 EST 2025
Sat Nov 29 07:25:09 EST 2025
Sun Apr 06 06:54:18 EDT 2025
Wed Apr 02 07:27:49 EDT 2025
Tue Oct 14 19:30:21 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords AR
GRADE
practice guideline
ARIA
Allergic Rhinitis and its Impact on Asthma
Grading of Recommendations Assessment, Development and Evaluation
Allergic rhinitis
Lung disease
Allergy
Immunopathology
Nose disease
Rhinitis
Respiratory disease
Recommendation
Asthma
Immunology
Revision
Professional practice
ENT disease
Bronchus disease
Obstructive pulmonary disease
Language English
License CC BY 4.0
Copyright (c) 2010 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c617t-6a84db6967e0b4d48df03745b4590ff0a6ccea6552eae78c3b1976e3ca08a8933
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Instructional Material/Guideline-3
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
PMID 20816182
PQID 1505300512
PQPubID 105664
PageCount 11
ParticipantIDs proquest_miscellaneous_817604653
proquest_miscellaneous_754016080
proquest_journals_1505300512
pubmed_primary_20816182
pascalfrancis_primary_23238968
crossref_citationtrail_10_1016_j_jaci_2010_06_047
crossref_primary_10_1016_j_jaci_2010_06_047
elsevier_sciencedirect_doi_10_1016_j_jaci_2010_06_047
elsevier_clinicalkeyesjournals_1_s2_0_S0091674910010572
elsevier_clinicalkey_doi_10_1016_j_jaci_2010_06_047
PublicationCentury 2000
PublicationDate 2010-09-01
PublicationDateYYYYMMDD 2010-09-01
PublicationDate_xml – month: 09
  year: 2010
  text: 2010-09-01
  day: 01
PublicationDecade 2010
PublicationPlace New York, NY
PublicationPlace_xml – name: New York, NY
– name: United States
– name: St. Louis
PublicationTitle Journal of allergy and clinical immunology
PublicationTitleAlternate J Allergy Clin Immunol
PublicationYear 2010
Publisher Elsevier Inc
Elsevier
Elsevier Limited
Publisher_xml – name: Elsevier Inc
– name: Elsevier
– name: Elsevier Limited
References Wallace, Dykewicz, Bernstein, Blessing-Moore, Cox, Khan (bib7) 2008; 122
Brozek, Baena-Cagnani, Bonini, Canonica, Rasi, van Wijk (bib9) 2008; 63
Costa, Bousquet, Ryan, Price, Demoly, Brozek (bib13) 2009; 18
Bousquet, Lund, Van Cauwenberge, Bremard-Oury, Mounedji, Stevens (bib3) 2003; 58
Brozek, Akl, Alonso-Coello, Lang, Jaeschke, Williams (bib17) 2009; 64
Guyatt, Oxman, Kunz, Vist, Falck-Ytter, Schunemann (bib15) 2008; 336
Church, Maurer, Simons, Bindslev-Jensen, van Cauwenberge, Bousquet (bib20) 2010; 65
Price, Bond, Bouchard, Costa, Keenan, Levy (bib5) 2006; 15
Schünemann, Jaeschke, Cook, Bria, El-Solh, Ernst (bib8) 2006; 174
Oxman, Schunemann, Fretheim (bib11) 2006; 4
Bousquet, van Cauwenberge, Ait Khaled, Bachert, Baena-Cagnani, Bouchard (bib21) 2006; 61
Ait-Khaled, Pearce, Anderson, Ellwood, Montefort, Shah (bib2) 2009; 64
(bib18) 2004; 59
Scadding, Durham, Mirakian, Jones, Leech, Farooque (bib6) 2008; 38
Guyatt, Oxman, Vist, Kunz, Falck-Ytter, Alonso-Coello (bib16) 2008; 336
Bousquet, Reid, van Weel, Baena Cagnani, Canonica, Demoly (bib19) 2008; 63
Bousquet, Van Cauwenberge, Khaltaev (bib4) 2001; 108
Hirsh, Guyatt (bib12) 2009; 374
Oxman, Schunemann, Fretheim (bib10) 2006; 4
Guyatt, Oxman, Kunz, Falck-Ytter, Vist, Liberati (bib14) 2008; 336
Bousquet, Khaltaev, Cruz, Denburg, Fokkens, Togias (bib1) 2008; 63
Schünemann (10.1016/j.jaci.2010.06.047_bib8) 2006; 174
Ait-Khaled (10.1016/j.jaci.2010.06.047_bib2) 2009; 64
Bousquet (10.1016/j.jaci.2010.06.047_bib4) 2001; 108
Hirsh (10.1016/j.jaci.2010.06.047_bib12) 2009; 374
Bousquet (10.1016/j.jaci.2010.06.047_bib3) 2003; 58
Oxman (10.1016/j.jaci.2010.06.047_bib11) 2006; 4
Scadding (10.1016/j.jaci.2010.06.047_bib6) 2008; 38
Bousquet (10.1016/j.jaci.2010.06.047_bib19) 2008; 63
Bousquet (10.1016/j.jaci.2010.06.047_bib21) 2006; 61
Guyatt (10.1016/j.jaci.2010.06.047_bib14) 2008; 336
Guyatt (10.1016/j.jaci.2010.06.047_bib16) 2008; 336
(10.1016/j.jaci.2010.06.047_bib18) 2004; 59
Price (10.1016/j.jaci.2010.06.047_bib5) 2006; 15
Costa (10.1016/j.jaci.2010.06.047_bib13) 2009; 18
Wallace (10.1016/j.jaci.2010.06.047_bib7) 2008; 122
Guyatt (10.1016/j.jaci.2010.06.047_bib15) 2008; 336
Brozek (10.1016/j.jaci.2010.06.047_bib9) 2008; 63
Church (10.1016/j.jaci.2010.06.047_bib20) 2010; 65
Bousquet (10.1016/j.jaci.2010.06.047_bib1) 2008; 63
Brozek (10.1016/j.jaci.2010.06.047_bib17) 2009; 64
Oxman (10.1016/j.jaci.2010.06.047_bib10) 2006; 4
21496893 - J Allergy Clin Immunol. 2011 Jun;127(6):1641-2; author reply 1643-5. doi: 10.1016/j.jaci.2011.01.071.
21481444 - J Allergy Clin Immunol. 2011 Jun;127(6):1640-1.e1; author reply 1643-5. doi: 10.1016/j.jaci.2011.01.070.
References_xml – volume: 4
  start-page: 19
  year: 2006
  ident: bib11
  article-title: Improving the use of research evidence in guideline development: 7. Deciding what evidence to include
  publication-title: Health Res Policy Syst
– volume: 336
  start-page: 995
  year: 2008
  end-page: 998
  ident: bib15
  article-title: What is “quality of evidence” and why is it important to clinicians?
  publication-title: BMJ
– volume: 174
  start-page: 605
  year: 2006
  end-page: 614
  ident: bib8
  article-title: An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations
  publication-title: Am J Respir Crit Care Med
– volume: 64
  start-page: 669
  year: 2009
  end-page: 677
  ident: bib17
  article-title: Grading quality of evidence and strength of recommendations in clinical practice guidelines. Part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions
  publication-title: Allergy
– volume: 108
  start-page: S147
  year: 2001
  end-page: S334
  ident: bib4
  article-title: Allergic rhinitis and its impact on asthma
  publication-title: J Allergy Clin Immunol
– volume: 4
  start-page: 28
  year: 2006
  ident: bib10
  article-title: Improving the use of research evidence in guideline development: 16
  publication-title: Evaluation. Health Res Policy Syst
– volume: 65
  start-page: 459
  year: 2010
  end-page: 466
  ident: bib20
  article-title: Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper
  publication-title: Allergy
– volume: 336
  start-page: 924
  year: 2008
  end-page: 926
  ident: bib16
  article-title: GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
  publication-title: BMJ
– volume: 64
  start-page: 123
  year: 2009
  end-page: 148
  ident: bib2
  article-title: Global map of the prevalence of symptoms of rhinoconjunctivitis in children: the International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three
  publication-title: Allergy
– volume: 59
  start-page: 373
  year: 2004
  end-page: 387
  ident: bib18
  article-title: ARIA in the pharmacy: management of allergic rhinitis symptoms in the pharmacy. Allergic rhinitis and its impact on asthma
  publication-title: Allergy
– volume: 61
  start-page: 1086
  year: 2006
  end-page: 1096
  ident: bib21
  article-title: Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaboration with GALEN)
  publication-title: Allergy
– volume: 122
  start-page: S1
  year: 2008
  end-page: S84
  ident: bib7
  article-title: The diagnosis and management of rhinitis: an updated practice parameter
  publication-title: J Allergy Clin Immunol
– volume: 63
  start-page: 38
  year: 2008
  end-page: 46
  ident: bib9
  article-title: Methodology for development of the Allergic Rhinitis and its Impact on Asthma guideline 2008 update
  publication-title: Allergy
– volume: 18
  start-page: 250
  year: 2009
  end-page: 257
  ident: bib13
  article-title: Guidelines for allergic rhinitis need to be used in primary care
  publication-title: Prim Care Respir J
– volume: 336
  start-page: 1049
  year: 2008
  end-page: 1051
  ident: bib14
  article-title: Going from evidence to recommendations
  publication-title: BMJ
– volume: 38
  start-page: 19
  year: 2008
  end-page: 42
  ident: bib6
  article-title: BSACI guidelines for the management of allergic and non-allergic rhinitis
  publication-title: Clin Exp Allergy
– volume: 63
  start-page: 8
  year: 2008
  end-page: 160
  ident: bib1
  article-title: Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)
  publication-title: Allergy
– volume: 63
  start-page: 990
  year: 2008
  end-page: 996
  ident: bib19
  article-title: Allergic rhinitis management pocket reference 2008
  publication-title: Allergy
– volume: 15
  start-page: 58
  year: 2006
  end-page: 70
  ident: bib5
  article-title: International Primary Care Respiratory Group (IPCRG) guidelines: management of allergic rhinitis
  publication-title: Prim Care Respir J
– volume: 58
  start-page: 733
  year: 2003
  end-page: 741
  ident: bib3
  article-title: Implementation of guidelines for seasonal allergic rhinitis: a randomized controlled trial
  publication-title: Allergy
– volume: 374
  start-page: 273
  year: 2009
  end-page: 275
  ident: bib12
  article-title: Clinical experts or methodologists to write clinical guidelines?
  publication-title: Lancet
– volume: 63
  start-page: 8
  issue: suppl 86
  year: 2008
  ident: 10.1016/j.jaci.2010.06.047_bib1
  article-title: Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)
  publication-title: Allergy
  doi: 10.1111/j.1398-9995.2007.01620.x
– volume: 58
  start-page: 733
  year: 2003
  ident: 10.1016/j.jaci.2010.06.047_bib3
  article-title: Implementation of guidelines for seasonal allergic rhinitis: a randomized controlled trial
  publication-title: Allergy
  doi: 10.1034/j.1398-9995.2003.00076.x
– volume: 108
  start-page: S147
  year: 2001
  ident: 10.1016/j.jaci.2010.06.047_bib4
  article-title: Allergic rhinitis and its impact on asthma
  publication-title: J Allergy Clin Immunol
  doi: 10.1067/mai.2001.118891
– volume: 63
  start-page: 990
  year: 2008
  ident: 10.1016/j.jaci.2010.06.047_bib19
  article-title: Allergic rhinitis management pocket reference 2008
  publication-title: Allergy
  doi: 10.1111/j.1398-9995.2008.01642.x
– volume: 174
  start-page: 605
  year: 2006
  ident: 10.1016/j.jaci.2010.06.047_bib8
  article-title: An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations
  publication-title: Am J Respir Crit Care Med
  doi: 10.1164/rccm.200602-197ST
– volume: 18
  start-page: 250
  year: 2009
  ident: 10.1016/j.jaci.2010.06.047_bib13
  article-title: Guidelines for allergic rhinitis need to be used in primary care
  publication-title: Prim Care Respir J
  doi: 10.4104/pcrj.2009.00028
– volume: 336
  start-page: 995
  year: 2008
  ident: 10.1016/j.jaci.2010.06.047_bib15
  article-title: What is “quality of evidence” and why is it important to clinicians?
  publication-title: BMJ
  doi: 10.1136/bmj.39490.551019.BE
– volume: 336
  start-page: 924
  year: 2008
  ident: 10.1016/j.jaci.2010.06.047_bib16
  article-title: GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
  publication-title: BMJ
  doi: 10.1136/bmj.39489.470347.AD
– volume: 122
  start-page: S1
  year: 2008
  ident: 10.1016/j.jaci.2010.06.047_bib7
  article-title: The diagnosis and management of rhinitis: an updated practice parameter
  publication-title: J Allergy Clin Immunol
  doi: 10.1016/j.jaci.2008.06.003
– volume: 4
  start-page: 19
  year: 2006
  ident: 10.1016/j.jaci.2010.06.047_bib11
  article-title: Improving the use of research evidence in guideline development: 7. Deciding what evidence to include
  publication-title: Health Res Policy Syst
  doi: 10.1186/1478-4505-4-19
– volume: 63
  start-page: 38
  year: 2008
  ident: 10.1016/j.jaci.2010.06.047_bib9
  article-title: Methodology for development of the Allergic Rhinitis and its Impact on Asthma guideline 2008 update
  publication-title: Allergy
  doi: 10.1111/j.1398-9995.2007.01560.x
– volume: 374
  start-page: 273
  year: 2009
  ident: 10.1016/j.jaci.2010.06.047_bib12
  article-title: Clinical experts or methodologists to write clinical guidelines?
  publication-title: Lancet
  doi: 10.1016/S0140-6736(09)60787-X
– volume: 64
  start-page: 123
  year: 2009
  ident: 10.1016/j.jaci.2010.06.047_bib2
  article-title: Global map of the prevalence of symptoms of rhinoconjunctivitis in children: the International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three
  publication-title: Allergy
  doi: 10.1111/j.1398-9995.2008.01884.x
– volume: 38
  start-page: 19
  year: 2008
  ident: 10.1016/j.jaci.2010.06.047_bib6
  article-title: BSACI guidelines for the management of allergic and non-allergic rhinitis
  publication-title: Clin Exp Allergy
  doi: 10.1111/j.1365-2222.2007.02888.x
– volume: 4
  start-page: 28
  year: 2006
  ident: 10.1016/j.jaci.2010.06.047_bib10
  article-title: Improving the use of research evidence in guideline development: 16
  publication-title: Evaluation. Health Res Policy Syst
  doi: 10.1186/1478-4505-4-28
– volume: 61
  start-page: 1086
  year: 2006
  ident: 10.1016/j.jaci.2010.06.047_bib21
  article-title: Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaboration with GALEN)
  publication-title: Allergy
  doi: 10.1111/j.1398-9995.2006.01144.x
– volume: 15
  start-page: 58
  year: 2006
  ident: 10.1016/j.jaci.2010.06.047_bib5
  article-title: International Primary Care Respiratory Group (IPCRG) guidelines: management of allergic rhinitis
  publication-title: Prim Care Respir J
  doi: 10.1016/j.pcrj.2005.11.002
– volume: 336
  start-page: 1049
  year: 2008
  ident: 10.1016/j.jaci.2010.06.047_bib14
  article-title: Going from evidence to recommendations
  publication-title: BMJ
  doi: 10.1136/bmj.39493.646875.AE
– volume: 64
  start-page: 669
  year: 2009
  ident: 10.1016/j.jaci.2010.06.047_bib17
  article-title: Grading quality of evidence and strength of recommendations in clinical practice guidelines. Part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions
  publication-title: Allergy
  doi: 10.1111/j.1398-9995.2009.01973.x
– volume: 59
  start-page: 373
  year: 2004
  ident: 10.1016/j.jaci.2010.06.047_bib18
  article-title: ARIA in the pharmacy: management of allergic rhinitis symptoms in the pharmacy. Allergic rhinitis and its impact on asthma
  publication-title: Allergy
  doi: 10.1111/j.1398-9995.2003.00468.x
– volume: 65
  start-page: 459
  year: 2010
  ident: 10.1016/j.jaci.2010.06.047_bib20
  article-title: Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper
  publication-title: Allergy
  doi: 10.1111/j.1398-9995.2009.02325.x
– reference: 21496893 - J Allergy Clin Immunol. 2011 Jun;127(6):1641-2; author reply 1643-5. doi: 10.1016/j.jaci.2011.01.071.
– reference: 21481444 - J Allergy Clin Immunol. 2011 Jun;127(6):1640-1.e1; author reply 1643-5. doi: 10.1016/j.jaci.2011.01.070.
SSID ssj0009389
Score 2.5804157
Snippet Allergic rhinitis represents a global health problem affecting 10% to 20% of the population. The Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines...
Background Allergic rhinitis represents a global health problem affecting 10% to 20% of the population. The Allergic Rhinitis and its Impact on Asthma (ARIA)...
Background: Allergic rhinitis represents a global health problem affecting 10% to 20% of the population. The Allergic Rhinitis and its Impact on Asthma (ARIA)...
SourceID proquest
pubmed
pascalfrancis
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 466
SubjectTerms Adult
Allergies
Allergy and Immunology
Asthma - drug therapy
Asthma - prevention & control
Asthma - therapy
Biological and medical sciences
Child
Child, Preschool
Children & youth
Colleges & universities
Desensitization, Immunologic - standards
Female
Fundamental and applied biological sciences. Psychology
Fundamental immunology
Guidelines as Topic - standards
Hospitals
Humans
Immunopathology
Infant
Infant, Newborn
Medical sciences
Non tumoral diseases
Otolaryngology
Otorhinolaryngology. Stomatology
practice guideline
Pregnancy
Rhinitis, Allergic, Perennial - drug therapy
Rhinitis, Allergic, Perennial - prevention & control
Rhinitis, Allergic, Perennial - therapy
Rhinitis, Allergic, Seasonal - drug therapy
Rhinitis, Allergic, Seasonal - prevention & control
Rhinitis, Allergic, Seasonal - therapy
Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis
Tobacco Smoke Pollution - adverse effects
Upper respiratory tract, upper alimentary tract, paranasal sinuses, salivary glands: diseases, semeiology
Title Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 Revision
URI https://www.clinicalkey.com/#!/content/1-s2.0-S0091674910010572
https://www.clinicalkey.es/playcontent/1-s2.0-S0091674910010572
https://dx.doi.org/10.1016/j.jaci.2010.06.047
https://www.ncbi.nlm.nih.gov/pubmed/20816182
https://www.proquest.com/docview/1505300512
https://www.proquest.com/docview/754016080
https://www.proquest.com/docview/817604653
Volume 126
WOSCitedRecordID wos000281512500008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVESC
  databaseName: ScienceDirect
  customDbUrl:
  eissn: 1097-6825
  dateEnd: 20200131
  omitProxy: false
  ssIdentifier: ssj0009389
  issn: 0091-6749
  databaseCode: AIEXJ
  dateStart: 19950101
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3rb9MwELfKhhASQrwpjMofmASqUsV52A7fuqqI8pgQG1K_WW7idC0lrZZ22l_D38pdnaTtSsdD4ktUxXHPyf3su7PvQchLEFqBl8IE1JE3cALmpY4MPeMIL0kZoChNuF4WmxDHx7Lfjz7Xaj_KWJiLicgyeXkZzf4rq-EeMBtDZ_-C3dWfwg34DUyHK7Adrn_E-DYG9w3RP_5shJ5BeXU-0CsiIjNgyvzsu0btsv2l18adgeEC812hDzzuEeDh9fLYIC_Ztq2_6iUdm76piq8cYbjJxk492PmHnfDwqGO-Wa_crPmxVTVOFzkIJnseYlZAPdIm005HDzNbcgr9UibTvNld65mNbNMJvu10ffcCD96j9d2LKqxmw-sT9D7mcGFzmVbLtI2sL_Dory26Aedr8juw9WS2RIPdpRi3xjoeFS59vOXadJ9XUm6f4ACQPlsWEBUg4vc9EUawau63e93--1VaZ19aA6sYcBGWZT0Ir1LapfrcmekcWJTaSiq7TZ2lynN6j9wteE3bFmP3Sc1kD8itT4U3xkPyoYQaLaFGAQwUoEYt1Og0oxZq9BUC7TVdwewNxTHTEmSPyNe33dPOO6cozuHEoPTOHa5lkAx4xIVxB0ESyCTFVEbhIAgjN01dzePYaB7CxNdGyNgfMNB8jR9rV2pQkv3HZC-bZuYpoRqbQM4xLHUAKqQ2QcoZ92QivBTs4Tph5XdTcZG5HguoTFTpojhW-K0Vjluhn2Yg6qRZ9ZnZvC3XPu2X7FDljAEZqgA71_YSv-pl8mI1yBVTuadctYWnOgmrnoWmazXY31JsbGClejWwiwCJXNbJQQketRoFWDlYlYIBXVo1gxjBs0GdGZjqSoDlxjiYj7sfkUxwF9Mx1skTC8sVeSzfw6T37J--43Nye7U0HJC9-fnCvCA34wvA7XmD3BB92Sgm3k9QFPpF
linkProvider Elsevier
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Allergic+Rhinitis+and+its+Impact+on+Asthma+%28ARIA%29+guidelines%3A+2010+Revision&rft.jtitle=Journal+of+allergy+and+clinical+immunology&rft.au=Bro%C5%BCek%2C+Jan+L.&rft.au=Bousquet%2C+Jean&rft.au=Baena-Cagnani%2C+Carlos+E.&rft.au=Bonini%2C+Sergio&rft.date=2010-09-01&rft.pub=Elsevier+Inc&rft.issn=0091-6749&rft.volume=126&rft.issue=3&rft.spage=466&rft.epage=476&rft_id=info:doi/10.1016%2Fj.jaci.2010.06.047&rft.externalDocID=S0091674910010572
thumbnail_m http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F00916749%2FS0091674910X00112%2Fcov150h.gif